Related Experiment Video
Updated: Jul 8, 2026
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH
Steve Titus1, Susanne Neumann, Wei Zheng
1National Institutes of Health Chemical Genomics Center, National Human Genome Research Institute, NIH, Bethesda, MD 20892-3370, USA.
Abstract:
The thyroid-stimulating hormone (TSH; thyrotropin) receptor belongs to the glycoprotein hormone receptor subfamily of 7-transmembrane spanning receptors. TSH receptor (TSHR) is expressed mainly in thyroid follicular cells and is activated by TSH, which regulates the growth and function of thyroid follicular cells. Recombinant TSH is used in diagnostic screens for thyroid cancer, especially in patients after thyroid cancer surgery. Currently, no selective small-molecule agonists of the TSHR are available. To screen for novel TSHR agonists, the authors miniaturized a commercially available cell-based cyclic adenosine 3',5' monophosphate (cAMP) assay into a 1536-well plate format. This assay uses an HEK293 cell line stably transfected with the TSHR coupled to a cyclic nucleotide gated ion channel as a biosensor. From a quantitative high-throughput screen of 73,180 compounds in parallel with a parental cell line (without the TSHR), 276 primary active compounds were identified. The activities of the selected active compounds were further confirmed in an orthogonal homogeneous time-resolved fluorescence cAMP-based assay. Forty-nine compounds in several structural classes have been confirmed as the small-molecule TSHR agonists that will serve as a starting point for chemical optimization and studies of thyroid physiology in health and disease.
Insights
Researchers identified novel small-molecule agonists for the thyroid-stimulating hormone (TSH) receptor. This discovery advances potential treatments for thyroid disorders and cancer by providing new tools for drug development.
Area of Science:
- Endocrinology
- Molecular Pharmacology
- Drug Discovery
Background:
- The thyroid-stimulating hormone (TSH) receptor (TSHR) is crucial for thyroid gland function and is a target in thyroid cancer diagnostics.
- Currently, selective small-molecule agonists for TSHR are unavailable, limiting therapeutic and research applications.
- Recombinant TSH is used clinically, but small molecules offer potential for more targeted interventions.
Purpose of the Study:
- To develop and validate a high-throughput screening (HTS) assay for identifying novel small-molecule TSHR agonists.
- To discover and confirm chemical compounds that activate the TSHR.
- To establish a foundation for chemical optimization and further research into thyroid physiology.
Main Methods:
- Miniaturization of a cell-based cyclic adenosine 3',5' monophosphate (cAMP) assay to a 1536-well plate format.
- Utilized a HEK293 cell line stably transfected with TSHR and coupled to a biosensor for screening.
- Conducted a quantitative HTS of 73,180 compounds, followed by orthogonal confirmation using a homogeneous time-resolved fluorescence cAMP assay.
Main Results:
- Identified 276 primary active compounds from the HTS screen.
- Confirmed 49 compounds as small-molecule TSHR agonists across several structural classes.
- Validated the assay's effectiveness in identifying functional TSHR activators.
Conclusions:
- Successfully identified novel small-molecule TSHR agonists through a miniaturized HTS campaign.
- These confirmed agonists represent valuable starting points for medicinal chemistry optimization.
- The findings provide new chemical tools for studying thyroid physiology and developing TSHR-targeted therapies.
